Test drug NX-2127 for hard-to-treat B-cell blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have a measurable, known B-cell cancer that has come back or is not responding to treatment.
- You must have had at least 2 prior systemic treatments (or at least 1 for certain cancers like Waldenström’s or PCNSL) and still need treatment.
- Your performance status is limited but acceptable (generally able to do self-care; lower numbers mean you’re doing better).
- Your blood counts, kidneys, and liver function meet study limits, and you’re not currently having serious uncontrolled illness.
- You can take the study medicine by mouth (swallow capsules) and meet medication/therapy timing rules (including contraception to prevent pregnancy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
This trial is testing a new drug, MDX2003, for people with certain types of lymphoma that have come back after at least two prior treatments. It aims to see how safe the drug is and if it can shrink tumors.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.